Sycamore Explores $10B Sale of UK Retailer Boots

Sycamore Partners is reportedly evaluating the divestiture of its prominent UK health and beauty chain, Boots, with preliminary discussions centering on a valuation approaching $10 billion. This strategic review is in its nascent stages, attracting early interest from a pool of international suitors keen on entering or expanding their footprint in the established British retail sector.

The potential sale marks a significant moment for Boots, a venerable institution in the UK health and beauty market since its inception in 1849. Recent financial disclosures highlight the company's robust performance, with revenues climbing 3.2% to £7.5 billion for the fiscal year concluding August 2025. Profit before tax saw a substantial increase of 25%, reaching £337 million, underscoring the brand's enduring appeal and operational efficiency under the recent leadership of Alex Baldock, formerly of Currys.

Sycamore Partners acquired Boots as part of a larger $23.7 billion transaction for Walgreens Boots Alliance in August 2025. Following this acquisition, the conglomerate was strategically segmented into five distinct operational units: Walgreens, Boots, Shields Health Solutions, CareCentrix, and VillageMD. This restructuring aimed to unlock value and allow each entity to pursue its specific market opportunities more effectively.

Among the interested parties is the influential Weston family of Canada, operating through their holding company Wittington Investments. Known for their ownership of grocery giant Loblaw and pharmacy operator Shoppers Drug Mart, the family has a history of significant retail transactions, including the 2022 sale of Selfridges for £4 billion. Their potential interest in Boots signals a continued appetite for high-profile UK retail assets.

Further signaling international interest, Australian healthcare group Sigma Healthcare has also entered preliminary discussions. Sigma Healthcare recently expanded its presence in the UK through a joint venture with GreenLight Healthcare, which manages 22 pharmacies in the London area, indicating a strategic push into the European market.

While these discussions are ongoing, sources stress that no definitive agreements have been reached. A successful trade sale would likely supersede earlier considerations by Sycamore Partners for a public listing of Boots on the London Stock Exchange. Such a divestiture would represent a substantial realization of capital for the private equity firm, capping off its ownership period with a potentially lucrative exit.

The health and beauty retail sector in the UK remains a competitive yet attractive market, driven by evolving consumer preferences for wellness and personalized care. With a market size estimated in the tens of billions, the sector offers significant scale for established players like Boots. The potential transaction underscores the ongoing consolidation and strategic realignments occurring within global retail and healthcare services, as private equity firms seek to optimize their portfolios.